Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of intramuscular FPP004X in healthy adults and patients with seasonal allergic rhinitis
jRCT2031250033Phase 1Active, not recruiting
- Sponsor
- FunPep
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FPP004X in seasonal allergic rhinitis (SAR) (4 arms), sponsored by FunPep. Primary endpoints: Safety and tolerability of FPP004X and Immunogenicity of FPP004X. Started Apr 2025; status: active, not recruiting.
02
Drugs
FPP004X
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on jRCT2031250033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250033.